Individualized Risk of Surgical Complications: An Application of the Breast Reconstruction Risk Assessment Score

John Y. S. Kim, MD*  
Alexei S. Mlodinow, BA*  
Nima Khavanin, BS*  
Keith M. Hume, MA†  
Christopher J. Simmons, BS†  
Michael J. Weiss, MPH‡  
Robert X. Murphy, Jr, MD, MS†  
Karol A. Gutowski, MD§

Background: Risk discussion is a central tenet of the dialogue between surgeon and patient. Risk calculators have recently offered a new way to integrate evidence-based practice into the discussion of individualized patient risk and expectation management. Focusing on the comprehensive Tracking Operations and Outcomes for Plastic Surgeons (TOPS) database, we endeavored to add plastic surgical outcomes to the previously developed Breast Reconstruction Risk Assessment (BRA) score.

Methods: The TOPS database from 2008 to 2011 was queried for patients undergoing breast reconstruction. Regression models were constructed for the following complications: seroma, dehiscence, surgical site infection (SSI), explantation, flap failure, reoperation, and overall complications.

Results: Of 11,992 cases, 4439 met inclusion criteria. Overall complication rate was 15.9%, with rates of 3.4% for seroma, 4.0% for SSI, 6.1% for dehiscence, 3.7% for explantation, 7.0% for flap loss, and 6.4% for reoperation. Individualized risk models were developed with acceptable goodness of fit, accuracy, and internal validity. Distribution of overall complication risk was broad and asymmetric, meaning that the average risk was often a poor estimate of the risk for any given patient. These models were added to the previously developed open-access version of the risk calculator, available at http://www.BRAscore.org.

Conclusions: Population-based measures of risk may not accurately reflect risk for many individual patients. In this era of increasing emphasis on evidence-based medicine, we have developed a breast reconstruction risk assessment calculator from the robust TOPS database. The BRA Score tool can aid in individualizing—and quantifying—risk to better inform surgical decision making and better manage patient expectations. (Plast Reconstr Surg Glob Open 2015;3:e405; doi: 10.1097/GOX.0000000000000351; Published online 28 May 2015.)
tectomy patients have shown steady yearly increases in the rate of reconstruction, leading to more than 90,000 reconstructions nationwide in 2011.4,5

Numerous modalities exist for reconstruction of the breast, and each carries its own advantages and disadvantages. A number of superb intrainstitutional studies have benchmarked rates and elucidated risk factors for complications in different modalities.6–20 Further, recent years have seen a greater number of studies using either meta-analysis or large-scale clinical registries with greater statistical power and generalizability.30–37 However, even given large-scale data, the reconstructive surgeon and mastectomy patient are still faced with the necessity of making an individualized decision based on these population-based measures of risk, which may over- or underestimate the actual probability of complications for the case at hand.

This conundrum has led to recent interest in online decision-making tools for patient and surgeon.28–31 The utility of these calculators lies in their ability to add specific and objective measures of risk to the conversation between patient and surgeon. In the face of these benefits, the Centers for Medicare and Medicaid Services may provide incentives to surgeons who discuss patient-specific risks before elective operations.32

The Breast Reconstruction Risk Assessment (BRA) score is an online tool (http://www.BRAScore.org), developed previously using the National Surgical Quality Improvement Program (NSQIP) to help assess the probability of complications based on the choice of reconstructive modality. The Tracking Operations and Outcomes for Plastic Surgeons (TOPS) program, maintained by the American Society of Plastic Surgeons (ASPS), provides more granular detail with respect to complications of interest in breast reconstruction. Our goal in this study was to use the TOPS database to expand upon the current BRA score model to include calculators for surgical complications of particular interest in breast reconstruction: seroma, dehiscence, surgical site infection (SSI), flap failure, explantation, and reoperation. The BRA score will never supplant clinical decision making; however, it can serve as a useful adjunct by transforming robust statistical analysis into an easy-to-use tool for patient and surgeon alike.

METHODS

Database

The TOPS database is a prospectively planned, Health Information Portability and Accountability Act (HIPAA)-compliant patient registry that was launched in 2002, with the goals of providing benchmarks and improving outcomes for members and candidate members of the ASPS.29 Since it began, data have been reported by more than 1200 surgeons, for over 1 million procedures.42 Data are self-reported and include procedure characteristics, clinical characteristics, and 30-day outcomes of interest to the plastic surgeon. Participation is voluntary and lacks financial incentives.

Patient Population

TOPS 2008–2011 dataset was queried for all patients undergoing immediate breast reconstruction. Patients undergoing autologous breast reconstruction were identified by Current Procedural Terminology codes 19361 (latissimus dorsi), 19364 (free flap), and 19367–19369 (pedicled Transverse Rectus Abdominus Myocutaneous [TRAM]). Patients undergoing prosthetic reconstruction were identified by Current Procedural Terminology code 19357. Procedures marked as “revisions” were excluded from analysis. In addition, patients marked as under 18 years old at the time of procedure, patients with outlier body mass index (BMI) of less than 10 or over 100, and duplicate cases were excluded from the cohort. Finally, patients without necessary preoperative data were excluded to allow for a robust analysis.

Clinical Characteristics and Outcomes

Variables of clinical interest tracked by TOPS include age, BMI, smoking status (30-day and lifetime), diabetes, and American Society of Anesthesiology (ASA) class. Outcomes of interest in this study were seroma, dehiscence, SSI, partial (10–90% of flap) or full flap loss, explantation (in the prosthetic cohort), and reoperation. SSI was defined as a superficial, deep, or organ space infection at the donor or recipient site. Flap failure was defined as partial (10–90%) or full (>90%) loss of the transferred tissue. More detailed information can be found in the TOPS Datapoint Definitions manual.43 For each complication, incidence was determined within each modality and within the population as a whole. Clinical characteristics of patients with a complication and those without one were compared using chi-square tests (Table 1). P values reported are two-sided, with a threshold of statistical significance at <0.05.
Risk Modeling

A random-intercept fixed-slope generalized linear model was used to estimate the risk for each of the 6 outcomes of interest, plus one for overall complications. All clinical characteristics in Table 1 were included in each model. Each risk model was used to calculate a predicted probability for its respective complication for each patient. Statistical analyses were performed using SPSS version 21.0 (IBM, Armonk, NY) and R version 3.0.1 (R Foundation for Statistical Computing, Vienna, Austria).

Risk Model Performance and Validation

Hosmer-Lemeshow statistics and c-statistics were ascertained to assess the calibration and discriminatory capacity of each model, respectively.45 Bootstrapping allows for the validation of a logistic regression model using the same dataset from which it was derived. It outperforms other commonly used validation methods.45–47 Bootstrapping with 1000 iterations was used to provide optimism-corrected c-statistics which, taken with uncorrected c-statistics, validate or nullify the discriminatory ability of each model. Additionally, model accuracy was validated with the Brier score.39

Risk Calculator

Each model was used to develop a calculator of predicted probabilities of its respective complication, using the inverse logit function: Probability = $1/(1 + e^{-\beta})$, where $\beta$ is equal to the model constant plus the covariates unique to a given patient. The online calculator (http://www.BRAScore.org) accepts clinical characteristics and provides predicted probabilities for each complication within each modality (Fig. 1).

This work is based on the TOPS program, which provides HIPAA-compliant, deidentified databases to members and candidate members of the ASPS.

RESULTS

Cohort Characteristics

A total of 11,992 prosthetic and autologous procedures were identified in the TOPS database files between 2008 and 2011. Four thousand four hundred thirty-nine met all inclusion criteria above and had no missing perioperative data. Of these, 3393 were prosthetic, 308 latissimus, 435 pedicled TRAM, and 230 free flaps. Overall incidence of complications was 3.4% for seroma, 4.0% for SSI, 6.1% for dehiscence, 3.7% for explantation, 7.0% for flap loss, and 6.4% for reoperation. Patients who experienced a complication were widely different from those who did not, in terms of clinical characteristics (Table 1).

Model Development and Risk Distribution

Seven binary logistic regression models were developed on the basis of the clinical characteristics displayed in Table 1. These models take into account 5 covariates in addition to reconstructive modality to determine a patient’s probability of a given outcome: age, BMI, smoking status, diabetes, and ASA class of greater than 2. The models themselves, represented by their $\beta$ values and intercepts, are displayed in Table 2. The minimum and maximum predicted probabilities are juxtaposed against the average or population-based risk estimate in Table 3. The broad spread of these values indicates that the population risk significantly over- or underestimates the risk for individual patients.

Model Performance

The model characteristics for that of each complication are shown in Table 4. The Hosmer-Lemeshow statistics showed all the models to be well calibrated (range, 0.167–0.609). The Brier score, which is 0

| Table 1. Clinical Comparison of Patients With Complications and Those Without |
|---------------------------------------------|
| No Complication | Any Complication |
| --- | --- | --- |
| $n = 3732$ | $n = 707$ |
| Age*† | 51.1 (44, 58) | 51.9 (45, 59) |
| BMI*† | 26.8 (22.6, 29.6) | 28.9 (23.7, 33.0) |
| Smoking | | |
| Former smoker* | 477 (12.78) | 112 (15.84) |
| Current smoker* | 321 (8.60) | 79 (11.17) |
| Diabetes* | 134 (3.59) | 46 (6.51) |
| ASA > 2* | 268 (7.18) | 78 (11.03) |
| Modality | | |
| Tissue Expander* | 2946 (78.94) | 447 (63.22) |
| Latissimus* | 251 (6.73) | 65 (9.19) |
| Pedicled TRAM* | 339 (9.08) | 141 (19.94) |
| Free Flap* | 196 (5.25) | 54 (7.64) |

*Statistical significance at $P < 0.05$. With respect to “modality,” this indicates that there is a statistically significant difference between the cohorts in the distribution of patients across reconstruction types.

†Continuous variables, which were analyzed using Mann-Whitney U tests and reported as mean (25th percentile, 75th percentile).
in an ideal model, ranged from 0.007 for the overall complication model to 0.063 for the flap failure model. Bootstrap validation yielded optimism-corrected c-statistics ranging from 0.603 for the reoperation model (0.612 uncorrected) to 0.677 for the flap failure model (0.699 uncorrected). Figures 2 and 3 consist of plots depicting observed versus expected outcomes for each model. Recent literature on risk modeling suggests that c-statistics in isolation may not represent a reliable measure of a model's validity. Specifically, for models with more homogenous cohorts, like the current examination of only one procedure, the c-statistic must be considered with other measures of predictive power. The optimism-corrected c-statistics demonstrate internal validity of all models. Further, Brier scores demonstrate predictive accuracy of all models.

Risk Calculator

These models served as the basis for an interactive risk calculator, which is freely available at http://www.BRAScore.org. The estimated risk of any of the

---

**Table 2. Betas for Each Predictive Model**

| Characteristic          | Seroma | Dehiscence | SSI | Flap Loss* | Explantation | Reoperation | Overall Complications |
|-------------------------|--------|------------|-----|------------|--------------|-------------|-----------------------|
| Age (per year)          | 0.007  | 0.000      | 0.002| 0.014      | 0.012        | 0.019       | 0.005                 |
| BMI (per point)         | 0.033  | 0.050      | 0.071| 0.018      | 0.082        | 0.041       | 0.048                 |
| Former smoker           | 0.256  | 0.154      | -0.345| 0.899      | -0.477       | 0.086       | 0.254                 |
| Current smoker          | -0.218 | 0.666      | 0.344| 0.515      | 0.202        | 0.572       | 0.450                 |
| Diabetic                | 0.141  | 0.074      | 0.294| 0.588      | 0.435        | -0.086      | 0.201                 |
| ASA > 2                 | 0.436  | 0.364      | 0.185| 0.218      | -0.175       | -0.338      | 0.216                 |
| Modality                |        |            |     |            |              |             |                       |
| Latissimus              | 1.193  | 0.328      | -0.208| —          | —            | -0.319      | 0.520                 |
| TRAM                    | 0.565  | 1.390      | 0.092| 1.399      | —            | 0.503       | 0.965                 |
| Free flap               | 0.413  | 0.549      | -0.745| 1.303      | —            | 0.607       | 0.589                 |
| Constants               | -4.957 | -4.581     | -5.277| -5.181     | -6.190       | -4.949      | -3.576                |

*Flap failure model uses latissimus as a reference, all others use tissue expander.
Table 3. Overall Incidences and Range of Predicted Probabilities

| Complication | Overall Incidence (%) | Minimum Probability (%) | Maximum Probability (%) |
|--------------|-----------------------|-------------------------|-------------------------|
| Seroma       | 3.37                  | 1.21                    | 22.24                   |
| SSI          | 3.96                  | 0.87                    | 29.89                   |
| Dehiscence   | 6.13                  | 2.22                    | 50.19                   |
| Flap failure | 7.0                   | 1.24                    | 50.57                   |
| Explantation | 3.7                   | 1.14                    | 52.08                   |
| Reoperation  | 6.42                  | 1.79                    | 23.01                   |
| Overall      | 15.92                 | 6.84                    | 62.50                   |

Minimum probability indicates the lowest predicted probability in the sample from which the models were derived. Maximum indicates the highest.

Table 4. Predictive Model Characteristics

| Complication | H-L Statistics | c-Statistics | Optimism Corrected H-L Statistics | Brier Score |
|--------------|----------------|--------------|-----------------------------------|-------------|
| Seroma       | 0.609          | 0.655        | 0.631                             | 0.032       |
| SSI          | 0.349          | 0.699        | 0.637                             | 0.038       |
| Dehiscence   | 0.167          | 0.672        | 0.661                             | 0.055       |
| Flap failure | 0.230          | 0.673        | 0.632                             | 0.063       |
| Explantation | 0.399          | 0.684        | 0.670                             | 0.035       |
| Reoperation  | 0.633          | 0.623        | 0.606                             | 0.059       |
| Overall      | 0.374          | 0.644        | 0.639                             | 0.128       |

In recent years, several evidence-based risk calculators have come into clinical use. Population-based estimates may not reflect the true magnitude of risk for patients at either extreme of the comorbidity spectrum, and the advantage of a risk calculator lies in its quantitative assessment of risk that is patient-specific. This obviates the need to rely on an impression that a patient is “low risk” or “high risk” and allows for a more precise dialogue between patient and surgeon. Further, the role of empirical and individualized data in surgical decision making and informed consent is growing increasingly important.

These questions and the hypothetical patients in Figures 2 and 3 highlight the importance of individualized risk scoring, and a simple and concrete tool such as the BRA score can facilitate decision making on the part of the surgeon and management of expectations on the part of the patient.

**DISCUSSION**

In recent years, several evidence-based risk calculators have come into clinical use. Population-based estimates may not reflect the true magnitude of risk for patients at either extreme of the comorbidity spectrum, and the advantage of a risk calculator lies in its quantitative assessment of risk that is patient-specific. This obviates the need to rely on an impression that a patient is “low risk” or “high risk” and allows for a more precise dialogue between patient and surgeon. Further, the role of empirical and individualized data in surgical decision making and informed consent is growing increasingly important.

Faced with the absence of a risk calculator for breast reconstruction, we previously developed the BRA score, an online risk calculator for SSI and medical complications, using the NSQIP database. Our goal in the current study is to expand on that model, using the TOPS database to add a risk calculator for surgical complications to the online interface.

The clinical utility of this calculator to the reconstructive surgeon is best exemplified by the concrete clinical examples seen in Figures 2 and 3, which display risk profiles taken from the online interface for 2 hypothetical patients with different clinical characteristics. Figure 2 represents a 45-year-old patient with a BMI of 19.4, no history of smoking or diabetes, and an ASA class of 1. It is clear to us that this patient has a low risk of flap failure compared to the population average of 7.0% (Table 3). However, she would likely grasp the concept better if given a more granular estimate, for example, that her risk of failure with a latissimus flap is only 1.47% (Fig. 2). Figure 3, on the other hand, represents a 70-year-old patient with a BMI of 32.3, a history of diabetes and smoking, and an ASA class of 3. Again, “intuition” tells us that she is at higher risk—but how high a risk? The pitfall of population-based risk is that we could inaccurately underestimate her individualized risk, in this case 27.7% for TRAM flap failure, a figure almost 5 times that of the population mean 7.0% (Table 3). Further, this risk is cut by two thirds when using a latissimus flap, with a failure risk of 9.1% (Fig. 3). In a case such as this, the resultant risk estimates may aid not only in the choice of flap type but also in the choice to delay or forego reconstruction.

Finally, the potential issues with overreliance on surgical intuition can come into play when there are patients with mixed risk profiles, for instance, how would we manage expectations in patients with a healthy gestalt profiles, but a single comorbidity? How do the vectors of risk in such a situation balance out? Quantitatively, this may be difficult to accurately assess and communicate. Further, a corollary to this is the question of how multiple risk factors interact. For example, what is the additive risk for someone with smoking history, diabetes, and obesity, and can we be more precise in capturing this summative risk? These questions and the hypothetical patients in Figures 2 and 3 highlight the importance of individualized risk scoring, and a simple and concrete tool such as the BRA score can facilitate decision making on the part of the surgeon and management of expectations on the part of the patient.
### Estimated Risk of Complication:

| Outcome                              | Tissue Expander | Pedicled Abdominal (TRAM) Flap | Latissimus Flap | Microvascular Reconstruction |
|--------------------------------------|-----------------|--------------------------------|-----------------|------------------------------|
| **Overall Medical Complications**    | 1.08%           | 3.98%                          | 1.49%           | 8.15%                        |
| **Overall Surgical Complications**   | 8.16%           | 18.90%                         | 13.00%          | 13.80%                       |
| Surgical Site Infection              | 1.61%           | 2.61%                          | 1.19%           | 2.70%                        |
| Seroma                               | 1.22%           | 2.13%                          | 3.93%           | 1.84%                        |
| Dehiscence                           | 2.63%           | 9.77%                          | 3.61%           | 4.46%                        |
| Flap Loss (Partial or Total)         | n/a             | 5.40%                          | 1.47%           | 5.22%                        |
| Explantion                           | 1.69%           | n/a                            | n/a             | n/a                          |
| 30-Day Reoperation                   | 3.56%           | 5.75%                          | 2.61%           | 6.34%                        |

1. Abstracted from NSQIP data
2. Abstracted from TOPS data

**Fig. 2.** Risk output: healthy patient predicted probability of each complication for a 45-year-old patient with a BMI of 19.4 (5’6” 120 lbs), no history of smoking or diabetes, and an ASA class of 1.

### Estimated Risk of Complication:

| Outcome                              | Tissue Expander | Pedicled Abdominal (TRAM) Flap | Latissimus Flap | Microvascular Reconstruction |
|--------------------------------------|-----------------|--------------------------------|-----------------|------------------------------|
| **Overall Medical Complications**    | 2.45%           | 8.69%                          | 3.35%           | 16.91%                       |
| **Overall Surgical Complications**   | 30.80%          | 53.88%                         | 42.81%          | 44.51%                       |
| Surgical Site Infection              | 7.56%           | 11.79%                         | 5.65%           | 12.16%                       |
| Seroma                               | 2.44%           | 4.22%                          | 7.62%           | 3.64%                        |
| Dehiscence                           | 13.44%          | 38.39%                         | 17.73%          | 21.18%                       |
| Flap Loss (Partial or Total)         | n/a             | 27.69%                         | 9.12%           | 26.97%                       |
| Explantion                           | 9.61%           | n/a                            | n/a             | n/a                          |
| 30-Day Reoperation                   | 10.46%          | 16.19%                         | 7.82%           | 17.65%                       |

1. Abstracted from NSQIP data
2. Abstracted from TOPS data

**Fig. 3.** Risk output: ill patient predicted probability of each complication for a 70-year-old patient with a BMI of 32.3 (5’6” 200 lbs), a history of diabetes and smoking, and an ASA class of 3.
The individual risk calculator based on the NSQIP database has strengths and weaknesses, and the TOPS database complements some of the weaknesses by providing surgical complications of particular interest to plastic and reconstructive surgeons. The TOPS database offers more granular complication data, including complications of particular interest to plastic and reconstructive surgeons. Our knowledge, this is one of the largest studies to examine surgical outcomes in breast reconstruction and the first study to provide a risk calculator for many of these surgical complications. The current analysis used 4439 patients from the TOPS database to augment the BRA score with a calculator for seroma, dehiscence, SSI, flap failure, explantation, and reoperation, as depicted in Figures 1–3. Average risk of each surgical complication in the overall cohort is displayed in Table 3. When comparing the TOPS rates with those of previous studies, the incidence of each complication was similar.6–28 The rates of SSI, reoperation, and dehiscence, 3 variables also tracked in NSQIP, were comparable to past studies using that database.9,13,26,27,35 There was some variation between procedure type, in keeping with recent literature.9,13,26,27,35 More telling, though, is the wide range of predicted risk. The mean probability of each complication lies in the midst of a broad distribution of predicted probabilities. Table 3 provides a numeric summary of the range for each, along with the mean probabilities (baseline incidence) for comparison. Although population-based means have an important role in benchmarking outcomes for cross-institutional comparison, it is clear that they grossly over- or underestimate risks for an individual patient. The range of predicted probabilities implies that most patients have their risk overestimated by the mean, whereas the outliers with the highest risk have their risk underestimated. For example, the rate of flap failure was 7.0% overall in the autologous cohort. Were this reported to a relatively young and healthy individual, it may be up to a 6-fold overestimate of her actual risk (minimum predicted probability was 1.2%). Conversely, were it reported to a relatively elderly and ill patient, it may be up to a 25-fold underestimate of her actual risk (maximum predicted probability was 50.6%).

There are some limitations to the BRA score and the TOPS database that need to be addressed. First, although TOPS has significant complication data that were previously unavailable in this magnitude, no large registry can capture all variables of interest to the specific procedures it tracks. For example, radiotherapy, hypertension, and surgeon experience would have made useful additions to the models, as they have been shown to alter risk of adverse outcomes in the context of both prosthetic and autologous breast reconstruction.23,25–27 Additionally, TOPS database classification precludes more specific classification of each reconstruction (eg, deep inferior epigastric perforator vs muscle-sparing TRAM) and control for mastectomy type. The BRA score was created with the goal of continuous improvement and developed to be easily modifiable, and any more granular information can be incorporated as it becomes available. Another limitation is the 30-day time course over which complications are tracked. While explantation and reoperation are 2 complications that may occur after this window, the authors feel that they remain adequately captured, particularly in the setting of emerging penalties for complications within this window. Finally, although these models were shown to be internally valid using the database from which they were derived, the ultimate test of their usefulness in clinical practice will come from analyzing their predictive power in other cohorts, a study that is currently under way.

Surgical complications lead to significant excesses in healthcare costs, length of hospital stay, and patient morbidity.6,26 Furthermore, hospital penalties for readmission, a common endpoint of many of these complications, are already in effect.57 For most patients, the risk is small. However, it is the outliers with high comorbidity burden for whom these calculators have the greatest clinical significance, allowing them to be identified and managed appropriately. The current analysis successfully used the robust cohort in the TOPS database to build on the previous BRA score with an individualized risk calculator for surgical complications: seroma, dehiscence, SSI, flap failure, explantation, and reoperation.

CONCLUSIONS

Management of expectations and honest, frank discussions of risk are a central tenet of the dialogue between patient and surgeon. The BRA score generated from the TOPS database follows the new and developing trend of moving beyond population-based metrics to a more individualized and quantitative discourse of risk and benefit. With the increasing emphasis on evidence-based medicine and quality measures, such individualized risk analysis can facilitate a better-informed discussion for our breast reconstruction patients.

John Y. S. Kim, MD
Division of Plastic and Reconstructive Surgery
Northwestern University Feinberg School of Medicine
675 North St. Clair Street
Galter Suite 19–250
Chicago, IL 60611
E-mail: jokim@nmh.org
REFERENCES

1. Wilkins EG, Cederna PS, Lowery JC, et al. Prospective analysis of psychosocial outcomes in breast reconstruction: one-year postoperative results from the Michigan Breast Reconstruction Outcome Study. Plast Reconstr Surg. 2000;106:1014–1025; discussion 1026–1027.

2. Aitsha D, Alderman AK, Lowery JC, et al. Prospective analysis of long-term psychosocial outcomes in breast reconstruction: two-year postoperative results from the Michigan Breast Reconstruction Outcomes Study. Ann Surg. 2008;247:1019–1028.

3. “The Women’s Health and Cancer Rights Act of 1998.” Available at: https://www.cms.gov/Regulations-and-Guidance/Health-Insurance-Reform/HealthInsReformForConsume/downloads/WHCRA_Helpful_Tips_2010_06_14.pdf. Accessed April 23, 2015.

4. Albornoz CR, Bach PB, Mehrara BJ, et al. A paradigm shift in U.S. Breast reconstruction: increasing implant rates. Plast Reconstr Surg. 2013;131:15–23.

5. American Society of Plastic Surgeons. 2011 Plastic Surgery Procedural Statistics. Available at: http://www.plasticsurgery.org/news-and-resources/2011-statistics-.html. Accessed November 1, 2013.

6. Adetayo OA, Salcedo SE, Biskup NI, et al. The battle of words and the reality of never events in breast reconstruction: incidence, risk factors predictive of occurrence, and economic cost analysis. Plast Reconstr Surg. 2012;130:29–29.

7. Chun YS, Verma K, Rosen H, et al. Implant-based breast reconstruction using acellular dermal matrix and the risk of postoperative complications. Plast Reconstr Surg. 2010;125:429–436.

8. Cordeiro PG, McCarthy CM. A single surgeon’s 12-year experience with tissue expander/implant breast reconstruction: part I. A prospective analysis of early complications. Plast Reconstr Surg. 2006;118:825–831.

9. Garvey PB, Villa MT, Rozanski AT, et al. The advantages of free abdominal-based flaps over implants for breast reconstruction in obese patients. Plast Reconstr Surg. 2012;130:991–1000.

10. Hartrampf CR Jr. The transverse abdominal island flap for breast reconstruction. A 7-year experience. Clin Plast Surg. 1988;15:703–716.

11. Kroll SS, Netscher DT. Complications of TRAM flap breast reconstruction in obese patients. Plast Reconstr Surg. 1989;84:886–892.

12. Lin KY, Johns FR, Gibson J, et al. An outcome study of breast reconstruction: presurgical identification of risk factors for complications. Ann Surg Oncol. 2001;8:586–591.

13. Losken A, Carlson GW, Schoemann MB, et al. Factors that influence the completion of breast reconstruction. Ann Plast Surg. 2004;52:258–261; discussion 262.

14. Nahabedian MY, Momen B, Galdino G, et al. Breast reconstruction with the free TRAM or DIEP flap: patient selection, choice of flap, and outcome. Plast Reconstr Surg. 2002;110:466–475; discussion 476–477.

15. Nahabedian MY, Tsangaris T, Momen B, et al. Infectious complications following breast reconstruction with expanders and implants. Plast Reconstr Surg. 2005;112:467–476.

16. Nguyen TJ, Costa MA, Vidar EN, et al. Effect of immediate reconstruction on postmastectomy surgical site infection. Ann Surg. 2012;256:326–333.

17. Padubidri AN, Yetman R, Browne E, et al. Complications of postmastectomy breast reconstructions in smokers, ex-smokers, and nonsmokers. Plast Reconstr Surg. 2001;107:342–349; discussion 350–351.

18. Paige KT, Bostwick J III, Bried JT, et al. A comparison of morbidity from bilateral, unipedicled and unilateral, unipedicled TRAM flap breast reconstructions. Plast Reconstr Surg. 1998;101:1819–1827.

19. Petersen A, Eftekharl A, Damsgaard TE. Immediate breast reconstruction: a retrospective study with emphasis on complications and risk factors. J Plast Surg Hand Surg. 2012;46:34–348.

20. Seth AK, Hirsch EM, Kim JV, et al. Hematoma after mastectomy with immediate reconstruction an analysis of risk factors in 883 patients. Ann Plast Surg. 2013;71:20–23.

21. Watterson PA, Bostwick J III, Hester TR Jr, et al. TRAM flap anatomy correlated with a 10-year clinical experience with 556 patients. Plast Reconstr Surg. 1995;95:1185–1194.

22. Woerdeman LA, Hage JJ, Hofland MM, et al. A prospective assessment of surgical risk factors in 400 cases of skin-sparing mastectomy and immediate breast reconstruction with implants to establish selection criteria. Plast Reconstr Surg. 2007;119:455–463.

23. Pinsolle V, Grinfeder C, Mathoulin-Pelissier S, et al. Complications analysis of 266 immediate breast reconstructions. J Plast Reconstr Aesthet Surg. 2006;59:1017–1024.

24. Leyngold MM, Stutman RL, Khiabani KT, et al. Contributing variables to post mastectomy tissue expander infection. Breast J. 2012;18:351–356.

25. McCarthy CM, Mehrara BJ, Riedel E, et al. Predicting complications following expander/implant breast reconstruction: an outcomes analysis based on preoperative clinical risk. Plast Reconstr Surg. 2008;121:1886–1892.

26. Fisher JP, Siever B, Nelson JA, et al. Comprehensive outcomes and cost analysis of free tissue transfer for breast reconstruction: an experience with 1903 flaps. Plast Reconstr Surg. 2013;131:195–203.

27. Gill PS, Hunt JP, Guerra AB, et al. A 10-year retrospective review of 758 DIEP flaps for breast reconstruction. Plast Reconstr Surg. 2004;113:1153–1160.

28. Khavanin N, Fine NA, Bethke KP, et al. Tumescent technique does not increase the risk of complication following mastectomy with immediate reconstruction. Ann Surg Oncol. 2014;21:384–388.

29. American Society of Plastic Surgeons. TOPS Brochure 2013. Available at: http://www.plasticsurgery.org/Documents/medical-professionals/TOPS%20Brochure%202013.pdf. Accessed November 5, 2013.

30. Khansa I, Momoh AO, Patel PP, et al. Fat necrosis in autologous abdomen-based breast reconstruction: a systematic review. Plast Reconstr Surg. 2013;131:443–452.

31. Kim JY, Davila AA, Persing S, et al. A meta-analysis of human acellular dermis and submuscular tissue expander breast reconstruction. Plast Reconstr Surg. 2012;129:28–41.

32. Gart MS, Smetona JT, Hanwright PJ, et al. Autologous options for postmastectomy breast reconstruction: a comparison of outcomes based on the American College of Surgeons National Surgical Quality Improvement Program. J Am Coll Surg. 2013;216:229–238.

33. Mioton LM, Smetona JT, Hanwright PJ, et al. Comparing thirty-day outcomes in prosthetic and autologous breast reconstruction: a multivariate analysis of 13,082 patients? J Plast Reconstr Aesthet Surg. 2013;66:917–925.

34. Davila AA, Seth AK, Wang E, et al. Human acellular dermis versus submuscular tissue expander breast reconstruction: a multivariate comparative analysis of short-term complications based on the National Surgical Quality Improvement Program (NSQIP) Database. Arch Plast Surg. 2013;40:19–27.
35. Hanwright PJ, Davila AA, Hirsch EM, et al. The differential effect of BMI on prosthetic versus autogenous breast reconstruction: a multivariate analysis of 12,986 patients. *Breast* 2013;22:938–943.

36. Mlodinow AS, Ver Halen JP, Lim S, et al. Predictors of readmission after breast reconstruction: a multi-institutional analysis of 5012 patients. *Ann Plast Surg* 2013;71:335–341.

37. Pannucci CJ, Antony AK, Wilkins EG. The impact of acellular dermal matrix on tissue expander/implant loss in breast reconstruction: an analysis of the tracking outcomes and operations in plastic surgery database. *Plast Reconstr Surg* 2013;132:1–10.

38. Cohen ME, Bilimoria KY, Ko CY, et al. Development of an American College of Surgeons National Surgery Quality Improvement Program: morbidity and mortality risk calculator for colorectal surgery. *J Am Coll Surg* 2009;208:1009–1016.

39. Bilimoria KY, Liu Y, Paruch JL, et al. Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons. *J Am Coll Surg* 2013;217:835–842.e1–e3.

40. Kim JY, Khavanin N, Jordan SW, et al. Individualized risk of surgical site infection: an application of the breast reconstruction risk assessment score. *Plast Reconstr Surg* 2014;134:351e–362e.

41. Kim JY, Mlodinow A, Khavanin N, et al. Abstract 31: Development of a Breast Reconstruction Risk Assessment (BRA) Score: an individualized risk calculator for complications using the NSQIP and TOPS databases. *Plast Reconstr Surg* 2014;133(4 Suppl):997.

42. National Quality Forum. Measure Application Partnership Pre-Rule Making Report 2013. Available at: http://www.qualityforum.org/Setting_Priorities/Partnership/2013_Pre-Rule Making_Final_Report.aspx. Accessed April 29, 2015.

43. Mlodinow AS, Kim JY, Khavanin N, Hume KM, Simmons CJ, Murphy RX Jr, Weiss MJ, Gutowski KA. Individualized Risk of Surgical Complications: An Application of the Breast Reconstruction Risk Assessment (BRA) Score. *Plast Reconstr Surg* 2014 Oct;134(4 Suppl 1):77–8.

44. American Society of Plastic Surgeons. TOPS Data Definitions. Available at: https://tops.plasticsurgery.org/DataPointDefinitions.html. Accessed January 17, 2014.

45. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med* 1996;15:361–387.

46. Altman DG, Royston P. What do we mean by validating a prognostic model? *Stat Med* 2000;19:453–473.

47. Steyerberg EW, Harrell FE Jr, Borsboom GJ, et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. *J Clin Epidemiol* 2001;54:774–781.

48. NIST/SEMATECH. “Measures of Skewness and Kurtosis.” e-Handbook of Statistical Methods. Available at: http://itl.nist.gov/div898/handbook/eda/section3/eda35b.htm. Accessed January 17, 2014.